BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
3/21/2024 11:37:41 AM | Browse: 325 | Download: 891
 |
Received |
|
2023-12-29 13:54 |
|
Peer-Review Started |
|
2023-12-29 13:54 |
|
First Decision by Editorial Office Director |
|
2024-01-19 00:56 |
|
Return for Revision |
|
2024-01-19 00:56 |
|
Revised |
|
2024-01-30 20:01 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-03-04 02:52 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-03-04 04:40 |
|
Articles in Press |
|
2024-03-04 04:40 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-03-07 06:23 |
|
Publish the Manuscript Online |
|
2024-03-21 11:37 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Editorial |
| Article Title |
Current remarks and future directions on the interactions between metabolic dysfunction-associated fatty liver disease and COVID-19
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Leonidas Brilakis, Eirini Theofilogiannakou and Panagis M Lykoudis |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Panagis M Lykoudis, MD, MSc, PhD, Lecturer, Division of Surgery & Interventional Science, University College London, Gower Street, London WC1E 6BT, United Kingdom. p.lykoudis@ucl.ac.uk |
| Key Words |
Metabolic dysfunction-associated fatty liver disease; COVID-19; Liver fibrosis; Cytokine storm; Drug induced liver injury |
| Core Tip |
The intricate intertwining of metabolic dysfunction-associated fatty liver disease (MAFLD) and coronavirus disease 2019 (COVID-19) presents a critical nexus with severe clinical outcomes. The symbiotic impact of MAFLD increasing susceptibility to severe COVID-19, and the reciprocal exacerbation by the viral infection, mandate special attention. Early identification, vigilant monitoring and tailored evidence-based interventions, navigating both conditions, are pivotal in mitigating adverse effects. Investigating the molecular pathways underlying the synergistic effects of MAFLD and COVID-19, and the impact of specific COVID-19 treatment drugs on liver function and their potential exacerbation of MAFLD, stands as a promising research avenue that could unveil novel therapeutic targets. |
| Publish Date |
2024-03-21 11:37 |
| Citation |
Brilakis L, Theofilogiannakou E, Lykoudis PM. Current remarks and future directions on the interactions between metabolic dysfunction-associated fatty liver disease and COVID-19. World J Gastroenterol 2024; 30(11): 1480-1487 |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i11/1480.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i11.1480 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
